Pharmacoeconomic aspects of hospital treatment of facial fractures - cost of illness study based on data from Balkan country with recent history of social and economic transition
Jana Desnica, M. Kostić, S. Jankovic, Sara Mijailovic, K. Parezanović Ilić, O. Milovanović, D. Vulovic
{"title":"Pharmacoeconomic aspects of hospital treatment of facial fractures - cost of illness study based on data from Balkan country with recent history of social and economic transition","authors":"Jana Desnica, M. Kostić, S. Jankovic, Sara Mijailovic, K. Parezanović Ilić, O. Milovanović, D. Vulovic","doi":"10.32383/appdr/157009","DOIUrl":null,"url":null,"abstract":"Background/purpose: The incidence of facial fractures has a tendency to rise, which positively correlates with increasing total costs of treating this medical condition. The aim of this study was to identify the total costs of the hospital treatment of facial fractures and to analyze its main determinants.\nMaterials and methods: This retrospective \"cost-of-illness\" study \"from bottom to the top\" approach was performed from the perspective of the Republic Health Insurance Fund. This study included 46 patients who were treated due to facial fractures at the Clinic for Maxillofacial Surgery at the Clinical Center Kragujevac in the period from the beginning of December 2017. to January 31, 2019.\nResults: The total costs of hospital treatment of all types of treated fractures amounted to 20,214.30€, and the average total cost per patient was estimated at 439.44±299.53€. The costs related to the length of hospitalization represented the largest part of the total direct costs, with a contribution of 31% and with a value of 6,329.30±80.18 €. \nConclusions: Results of this pilot study pointed out that the total costs of treating facial fractures in the socio-economic sphere of Balkan countries are lower than in other health care systems, mostly due to differences in valuing medical services compared to countries within the European Union. Due to the rising incidence of injuries and obligatory hospital treatment of these conditions, this kind of pharmacoeconomic evaluation could contribute to the introduction of new therapeutic strategies for adequate allocation of resources within health systems.","PeriodicalId":7147,"journal":{"name":"Acta poloniae pharmaceutica","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta poloniae pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32383/appdr/157009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/purpose: The incidence of facial fractures has a tendency to rise, which positively correlates with increasing total costs of treating this medical condition. The aim of this study was to identify the total costs of the hospital treatment of facial fractures and to analyze its main determinants.
Materials and methods: This retrospective "cost-of-illness" study "from bottom to the top" approach was performed from the perspective of the Republic Health Insurance Fund. This study included 46 patients who were treated due to facial fractures at the Clinic for Maxillofacial Surgery at the Clinical Center Kragujevac in the period from the beginning of December 2017. to January 31, 2019.
Results: The total costs of hospital treatment of all types of treated fractures amounted to 20,214.30€, and the average total cost per patient was estimated at 439.44±299.53€. The costs related to the length of hospitalization represented the largest part of the total direct costs, with a contribution of 31% and with a value of 6,329.30±80.18 €.
Conclusions: Results of this pilot study pointed out that the total costs of treating facial fractures in the socio-economic sphere of Balkan countries are lower than in other health care systems, mostly due to differences in valuing medical services compared to countries within the European Union. Due to the rising incidence of injuries and obligatory hospital treatment of these conditions, this kind of pharmacoeconomic evaluation could contribute to the introduction of new therapeutic strategies for adequate allocation of resources within health systems.
期刊介绍:
The international journal of the Polish Pharmaceutical Society is published in 6 issues a year. The journal offers Open Access publication of original research papers, short communications and reviews written in English, in all areas of pharmaceutical sciences. The following areas of pharmaceutical sciences are covered: Analysis, Biopharmacy, Drug Biochemistry, Drug Synthesis, Natural Drugs, Pharmaceutical Technology, Pharmacology and General.
A bimonthly appearing in English since 1994, which continues “Acta Poloniae Pharmaceutica”, whose first issue appeared in December 1937. The war halted the activity of the journal’s creators. Issuance of “Acta Poloniae Pharmaceutica” was resumed in 1947. From 1947 the journal appeared irregularly, initially as a quarterly, then a bimonthly. In the years 1963 – 1973 alongside the Polish version appeared the English edition of the journal. Starting from 1974 only works in English are published in the journal. Since 1995 the journal has been appearing very regularly in two-month intervals (six books a year). The journal publishes original works from all fields of pharmacy, summaries of postdoctoral dissertations and laboratory notes.